FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to gastroenterology and can be used to treat experimental ulcerative colitis in rats. The method includes rectal administration of ozone in the form of an ozone-oxygen mixture with an ozone concentration of 2.5 mg/l in a volume of 10 cm3, a dose of 0.1 mg/kg, once a day, a course of treatment for 6 days.
EFFECT: invention provides high efficiency, absence of side effects, allergic reactions, resistance to this method does not develop.
1 cl, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR INTRAPERITONEAL APPLICATION OF MEDICAL OZONE FOR TREATING ULCERATIVE COLITIS | 2021 |
|
RU2782488C1 |
| METHOD FOR TREATING ULCERATIVE COLITIS | 2000 |
|
RU2165758C1 |
| MELATONIN AGENT FOR TREATING INFLAMMATORY BOWEL DISEASES IN THE FORM OF RECTAL SUPPOSITORIES | 2023 |
|
RU2819721C1 |
| AGENT WITH VITAMIN D3 FOR TREATING ULCERATIVE COLITIS IN THE FORM OF RECTAL SUPPOSITORIES | 2019 |
|
RU2709209C1 |
| METHOD FOR TREATING INFLAMMATORY DISEASES OF TERMINAL COLON | 2022 |
|
RU2807235C1 |
| KOBITOLIMOD FOR USE IN TREATMENT OF INFLAMMATORY BOWEL DISEASE | 2018 |
|
RU2766356C2 |
| METHOD FOR EVALUATING CLINICAL EFFECTIVENESS IN ULCERATIVE COLITIS | 2012 |
|
RU2504779C1 |
| METHOD OF TREATING ULCERATIVE COLITIS | 2023 |
|
RU2807131C1 |
| METHOD OF TREATING ULCERATIVE COLITIS | 2023 |
|
RU2814765C1 |
| DOSAGE FORM FOR TREATING AND PREVENTING ULCERATIVE COLITIS, CONTAINING PEGYLATED LIPOSOMAL FORM OF ERYTHROPOIETIN IN FORM OF SUPPOSITORIES, HAVING ANTI-INFLAMMATORY AND IMMUNOMODULATORY EFFECT | 2020 |
|
RU2740060C1 |
